Lotte Jensen1,2, Susan Nielsen3, Anne Estmann Christensen4, Freddy Karup Pedersen3, Ramona Trebbien5, Thea Kølsen Fischer5, Susanne Rosthøj6, Peter Toftedal4, Anna-Helene Bohr7, Peder Skov Wehner4, Anja Poulsen3. 1. The Department of Paediatrics and Adolescent Medicine, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. lotte.jensen@regionh.dk. 2. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. lotte.jensen@regionh.dk. 3. The Department of Paediatrics and Adolescent Medicine, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 4. The Department of Paediatrics and Adolescent Medicine, Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark. 5. Department of Virus and Microbiological Special diagnostics, National Influenza Center, Statens Serum Institut, Copenhagen, Denmark. 6. Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. 7. The Department of Paediatrics, Naestved Hospital, Naestved, Denmark.
Abstract
BACKGROUND: Prevention of illness due to infection by influenza viruses is important for children with rheumatic diseases. Biological disease modifying antirheumatic drugs have become increasingly important in the treatment of juvenile idiopathic arthritis, and combinations of immunosuppressive drugs are used for the treatment of systemic disorders, which increase the risk of secondary immunodeficiency. Therefore, we investigated whether children with rheumatic disease can mount a protective antibody response after influenza immunization. METHODS: The prospective multicentre cohort study was conducted in Denmark during the influenza season 2015-2016. Children with rheumatic disease aged six months to 19 years were eligible. Controls were immunologically healthy children. A blood sample was collected before and after vaccination and analysed by haemagglutination inhibition (HI) assay for the 2015-2016 influenza vaccine-strains. In case of flu-like symptoms the child was tested for influenza. For statistical analyses the patients were grouped according to medical treatment or disease. RESULTS: A total of 226 patients and 15 controls were enrolled. No differences were found for the increase of antibodies from pre-vaccine to post-vaccine between the groups in our primary analyses: A/Cal H1N1pdm09 (p = 0.28), A/Swi H3N2 (p = 0.15) and B/Phu Yamagata (p = 0.08). Only when combining patients across groups a lower increase in antibodies was found compared to controls. Among all patients the pre-vaccine rates for seroprotection using the HI-titer cut-off ≥ 40 were 93.1-97.0 % for all three strains. For seroprotection using the HI-titer cut-off ≥ 110 the pre-vaccine rates for all patients were 14.9-43.6 % for all three strains and an increase in the proportions of patients being seroprotected after vaccination was found for A/Cal H1N1pdm09 and A/Swi H3N2. None of the children with flu-like symptoms tested positive for the vaccine strains. CONCLUSIONS: Children with rheumatic diseases increase in antibody titres after influenza immunization, however, it remains uncertain whether a protective level is achieved.
BACKGROUND: Prevention of illness due to infection by influenza viruses is important for children with rheumatic diseases. Biological disease modifying antirheumatic drugs have become increasingly important in the treatment of juvenile idiopathic arthritis, and combinations of immunosuppressive drugs are used for the treatment of systemic disorders, which increase the risk of secondary immunodeficiency. Therefore, we investigated whether children with rheumatic disease can mount a protective antibody response after influenza immunization. METHODS: The prospective multicentre cohort study was conducted in Denmark during the influenza season 2015-2016. Children with rheumatic disease aged six months to 19 years were eligible. Controls were immunologically healthy children. A blood sample was collected before and after vaccination and analysed by haemagglutination inhibition (HI) assay for the 2015-2016 influenza vaccine-strains. In case of flu-like symptoms the child was tested for influenza. For statistical analyses the patients were grouped according to medical treatment or disease. RESULTS: A total of 226 patients and 15 controls were enrolled. No differences were found for the increase of antibodies from pre-vaccine to post-vaccine between the groups in our primary analyses: A/Cal H1N1pdm09 (p = 0.28), A/Swi H3N2 (p = 0.15) and B/Phu Yamagata (p = 0.08). Only when combining patients across groups a lower increase in antibodies was found compared to controls. Among all patients the pre-vaccine rates for seroprotection using the HI-titer cut-off ≥ 40 were 93.1-97.0 % for all three strains. For seroprotection using the HI-titer cut-off ≥ 110 the pre-vaccine rates for all patients were 14.9-43.6 % for all three strains and an increase in the proportions of patients being seroprotected after vaccination was found for A/Cal H1N1pdm09 and A/Swi H3N2. None of the children with flu-like symptoms tested positive for the vaccine strains. CONCLUSIONS:Children with rheumatic diseases increase in antibody titres after influenza immunization, however, it remains uncertain whether a protective level is achieved.
Authors: Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: M W Heijstek; L M Ott de Bruin; M Bijl; R Borrow; F van der Klis; I Koné-Paut; A Fasth; K Minden; A Ravelli; M Abinun; G S Pileggi; M Borte; N M Wulffraat Journal: Ann Rheum Dis Date: 2011-08-03 Impact factor: 19.103
Authors: F Kanakoudi-Tsakalidou; M Trachana; P Pratsidou-Gertsi; E Tsitsami; V Kyriazopoulou-Dalaina Journal: Clin Exp Rheumatol Date: 2001 Sep-Oct Impact factor: 4.473
Authors: Jasvinder A Singh; George A Wells; Robin Christensen; Elizabeth Tanjong Ghogomu; Lara Maxwell; John K Macdonald; Graziella Filippini; Nicole Skoetz; Damian Francis; Luciane C Lopes; Gordon H Guyatt; Jochen Schmitt; Loredana La Mantia; Tobias Weberschock; Juliana F Roos; Hendrik Siebert; Sarah Hershan; Michael Pt Lunn; Peter Tugwell; Rachelle Buchbinder Journal: Cochrane Database Syst Rev Date: 2011-02-16
Authors: Timothy Beukelman; Fenglong Xie; Lang Chen; John W Baddley; Elizabeth Delzell; Carlos G Grijalva; James D Lewis; Rita Ouellet-Hellstrom; Nivedita M Patkar; Kenneth G Saag; Kevin L Winthrop; Jeffrey R Curtis Journal: Arthritis Rheum Date: 2012-08